CSTL News

Merlin CP-GEP Becomes the First and Only Gene Expression Profile (GEP) Test Recommended by NCCN® Cutaneous Melanoma Guidelines to Assess Metastatic Risk

Orion Nuclear Energy Corporation and Constellis Announce Strategic Collaboration to Advance Security Standards for Nuclear and Critical Infrastructure

Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026

Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma

Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer

Expert Melanoma Panel Recommends Castle Biosciences’ DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma

Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year

New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity